Retension Pharmaceuticals, Inc. RTSN
Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) is a cardio-renal-metabolic drug developer. Its lead program, RTN-001, is in Phase 2 for Uncontrolled hypertension (also resistant hypertension). Its next catalyst on record is RTN-001: Initial data from Phase 2b dose-ranging trial in uncontrolled hypertension (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RTN-001 — Initial data from Phase 2b dose-ranging trial in uncontrolled hypertension (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RTN-001 (once-daily oral PDE-5 inhibitor) | Uncontrolled hypertension (Phase 2b dose-ranging); resistant hypertension | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.